Dermatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Arch Dermatol Res. 2018 Jan;310(1):39-46. doi: 10.1007/s00403-017-1792-6. Epub 2017 Nov 10.
Janus kinases (JAKs) are non-receptor protein tyrosine kinases that are expressed in many tissues. Once the JAKs are activated, a cascade of further signaling events is triggered involving phosphorylation of selected receptor chain tyrosines, binding of signal transducer and activator of transcription (STAT) proteins and phosphorylation of these STATs. Due to their ability to selectively modulate immune function, targeted JAK inhibitors are promising candidates for some skin diseases such as psoriasis and atopic dermatitis. The aim of this study was to assess the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases. This study was conducted on 10 patients with psoriasis, 10 patients with vitiligo and 10 controls. JAK1 levels before and after treatment with NB-UVB 311 nm (36 sessions) were measured using Western blot assay. The level of JAK1 was significantly higher in vitiligo and psoriasis patients than controls. There was a decline in the level of JAK1 after treatment, which was statistically significant. VASI and PASI scores of patients decreased after treatment with NB-UVB. In psoriatic patients, the JAK1 level positively correlated with the female participants, disease duration and PASI change. It was concluded that JAK1 plays a role in the pathogenesis of both vitiligo and psoriasis based on its upregulated level before treatment and downregulated level after treatment. This raises the possibility of using the JAK1 inhibitors as targeted immunotherapy for vitiligo and psoriasis.
Janus 激酶（JAKs）是非受体蛋白酪氨酸激酶，在许多组织中表达。一旦 JAK 被激活，就会触发一连串进一步的信号事件，涉及到选定受体链酪氨酸的磷酸化、信号转导和转录激活因子（STAT）蛋白的结合以及这些 STAT 的磷酸化。由于它们能够选择性地调节免疫功能，靶向 JAK 抑制剂是一些皮肤病（如银屑病和特应性皮炎）的有前途的候选药物。本研究旨在评估 NB-UVB 治疗前后白癜风和银屑病患者 JAK1 的水平，NB-UVB 被认为是这两种疾病的金标准治疗方法。本研究共纳入 10 例银屑病患者、10 例白癜风患者和 10 例对照。使用 Western blot 检测 NB-UVB 311nm（36 次）治疗前后 JAK1 的水平。与对照组相比，白癜风和银屑病患者的 JAK1 水平显著升高。治疗后 JAK1 水平下降，具有统计学意义。NB-UVB 治疗后患者的 VASI 和 PASI 评分降低。在银屑病患者中，JAK1 水平与女性参与者、疾病持续时间和 PASI 变化呈正相关。结论：基于治疗前 JAK1 水平上调和治疗后 JAK1 水平下调，JAK1 在白癜风和银屑病的发病机制中起作用。这为使用 JAK1 抑制剂作为白癜风和银屑病的靶向免疫疗法提供了可能性。
